#1wcg Investor Roadshow Presentation July 2021 wcg#2Disclaimer Notice to and Undertaking by Recipients This presentation has been made available to you with the consent of WCG Clinical, Inc. (WCG", "we", "us" or "our). The Company has filed a registration statement (including a preliminary prospectus) on Form S-1 (File No. 333-257611) with the SEC for the offering to which this presentation relates. The registration statement has not yet become effective. The securities proposed to be offered pursuant to such registration statement may not be sold, nor may offers to buy be accepted, prior to the time the registration statement becomes effective. Before you invest, you should read the preliminary prospectus in that registration statement and other documents the Company has filed with the SEC for more complete information about the Company and this offering. You may get these documents for free by visiting the SEC website at http://www.sec.gov. Alternatively, copies of the prospectus may be obtained from Goldman Sachs & Co. LLC, 200 West Street, New York, New York 10282, Attn: Prospectus Department, Telephone: (866) 471-2526, Email [email protected], BotA Securities, Inc., NC1-004-03-43, 200 North College Street, 3rd Floor, Charlotte, NC 28255-0001, Attn: Prospectus Department. [email protected] and Morgan Stanley & Co. LLC, Attn: Prospectus Department, 180 Varick Street, 2nd Floor, New York, NY 10014. This presentation shall not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. Forward-Looking Statements. This presentation contains forward-looking statements that are subject to risks and uncertainties. All statements other than statements of historical fact or relating to present facts or current conditions included in this presentation are forward-looking statements Forward-looking statements give our current expectations and projections relating to our financial condition, results of operations, plans, objectives, future performance and business. You can identify forward-looking statements by the fact that they do not relate strictly to historical or current facts. These statements may include words such as "anticipate," "believe," "continue." "could." "estimate," "expect," intend," "may." "might "plan" "potential," "predict" "seek," "vision," or "should," or the negative thereof, and other words and terms of similar meaning in connection with any discussion of the timing or nature of future operating or financial performance or other events but not all forward-looking statements contain these identifying words. The forward-looking statements contained in this presentation are based on assumptions that we have made in light of our industry experience and our perceptions of historical trends, current conditions, expected future developments and other factors that we believe are appropriate under the circumstances. As you consider this presentation, you should understand that these statements are not guarantees of performance or results. These assumptions and our future performance or results involve risks and uncertainties (many of which are beyond our control). Forward-looking statements include, but are not limited to, those we make regarding the following matters: our ability to successfully increase our client base and expand our relationships and the products, technologies and services we provide to our existing clients; our ability to execute our business plan and manage our recent growth, developments regarding our competitors and our industry; our ability to attract and retain highly skilled employees and contingent workers; our ability to detect and respond to defects or disruptions in our solutions; our ability to acquire and successfully integrate other companies or technologies, our the satisfaction of our customers with the professional services provided by us or our partners, or with our technical support services to the effect of laws and regulations related to compliance with economic sanctions; our estimate of the market size for our solutions we have provided publicly; our ability to realize anticipated revenue reflected in our bookings and client engagements; from the effect of natural disasters and epidemic diseases, such as the recent COVID-19 pandemic; changes in the biopharmaceutical industry that could adversely affect our business, including mergers within the biopharmaceutical industry or regulatory changes, increased competition and delays in the drug discovery and development process; the impact of contracts terminations, or reductions in the scope of work, the impact of lawsuits from third parties for alleged infringement of their proprietary rights or misappropriation or other violation of intellectual property: the effects of laws and regulations related to privacy and data protection; the impact of current and future litigation against us. Any forward-looking statement made by us in this presentation speaks only as of the date on which it is made. We undertake no obligation to publicly update any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by low. Furthermore, the potential impact of the COVID-19 pandemic on our business operations and financial results and on the world economy as a whole may heighten the risks and uncertainties that affect our forward-looking statements described above. Additional factors or events that could cause our actual performance to differ from these forward-looking statements may emerge from time to time, and it is not possible for us to predict all of them. Should one or more of these risks or uncertainties materialize, or should any of our assumptions prove incorrect, our actual financial condition, results of operations, future performance and business may vary in material respects from the performance projected in these forward-looking statements Industry Information This presentation includes estimates regarding market and industry data that we prepared based on our management's knowledge and experience in the markets in which we operate, together with information obtained from various sources, including publicly available information, industry reports and publications, surveys, our customers, distributors, suppliers, trade and business organizations and other contacts in the markets in which we operate. Management estimates are derived from publicly available information released by independent industry analysts and third-party sources, as well as data from our internal research, and are based on assumptions made by us upon reviewing such data and our knowledge of such industry and markets which we believe to be reasonable. In presenting this information, we have made certain assumptions that we believe to be reasonable based on such data and other similar sources and on our knowledge of, and our experience to date in, the markets we serve. Market share data is subject to change and may be limited by the availability of raw data, the voluntary nature of the data gathering process and other limitations inherent in any statistical survey of market share. In addition, customer preferences are subject to change. Accordingly, you are cautioned not to place undue reliance on such market share data. Basis of Presentation. The Company purchased all of the equity interests in its business from WCG HoldCo IV LLC (the "Seller) on January 8, 2020. As a result, the Company's financial information prior to and including December 31, 2019 included in this presentation represent the financial information of Seller. In light of the proximity of January 8, 2020 to the start of the January 2020 accounting period, the Company has elected to present the results from January 1 through January 7, 2020 in the year ended December 31, 2020 and the quarter ended March 31, 2020 Non-GAAP Financial Measures We present Adjusted EBITDA, which is not a recognized financial measure under U.S. generally accepted accounting principles, because we believe it assists investors and analysts in comparing our operating performance across reporting periods on a consistent basis by excluding items that we do not believe are indicative of our core operating performance. We define "Adjusted EBITDA" as net (loss) income excluding interest expense, income taxes, depreciation and amortization, stock option expense, integration costs, acquisition related adjustments, restructuring costs, litigation costs, change in value of contingent consideration, management fees, charitable contributions and other items not indicative of our ongoing operating performance. You are encouraged to evaluate these adjustments and the reasons we consider them appropriate for supplemental analysis. In evaluating Adjusted EBITDA, you should be aware that in the future we may incur expenses that are the same as or similar to some of the adjustments in our presentation of Adjusted EBITDA. Our presentation of Adjusted EBITDA should not be construed as an inference that our future results will be unaffected by unusual or non-recurring items. There can be no assurance that we will not modify the presentation of Adjusted EBITDA in the future, and any such modification may be material. In addition, Adjusted EBITDA may not be comparable to similarly titled measures used by other companies in our industry or across different industries. See the appendix to this presentation for a reconciliation of Adjusted EBITDA to the nearest GAAP measure 2 wcg#3Today's Presenters Don Deieso, PhD Founder, Executive Chairman & Chief Executive Officer 40 Years of Experience Laurie Jackson, CPA Chief Financial Officer & Chief Administration Officer 30 Years of Experience Nick Slack, MBE President & Chief Commercial Officer 15 Years of Experience DNL wcg#4Executive Summary wcg™#55 WCG Mission: To Reduce Time and Cost of Clinical Trials Discovery & Development Early Drug Discovery -56% of Total Time -29% of Total Cost Pre-Clinical Research IND 1 I 1 1 1 1 Phase I Trial Clinical Trials Sources: 2019 Tufts center for the study of drug development Published in Journal of Health Economics IND = Investigational New Drug application, which provides approval for human clinical trials to start. NDA= New Drug Application, which provides approval for sale and marketing. Phase II Trial -44% of Total Time: -71% of Total Cost: Phase III Trial + Approval NDA Up to 10-15 Years Up to $2.6bn Post-Approval Phase IV DN L wcg WCG Mission: To Reduce Time & Cost of Clinical Trials wcg By Offering Solutions to Address the Critical Pain Points I#6Our Vision & Organization Our Vision Getting Needed Cures to Patients Faster Provide clinical trial stakeholders with the highest-quality service, accelerate the scientific advancement of human health, and ensure that the risks of progress never outweigh the value of human life. (1) Through predecessor companies. Our Organization DN L Celebrating 50+ years(¹) of Supporting Clinical Trials wcg™ Ethical Review Segment Our WCG IRB and IBC Services maximize research participant protections and save essential time in pursuit of clinical discovery Clinical Trials Solutions Segment Our highly specialized services have been designed to address critical pain points that can enhance or derail quality outcomes. 52% of 2020 Revenue 48% of 2020 Revenue#7WCG Participates in 90% of Global Clinical Trials(¹) - Extensive Reach and Expertise Princeton, NJ (Corporate) Hamilton, NJ Philadelphia, PA Cary, NC Puyallup, WA New York, NY Boston, MA Cambridge, MA Los Angeles, CA San Francisco, CA San Diego, CA Kansas City, KS Madison, WI Minneapolis, MN Chicago, IL Indianapolis, IN Vancouver, BC, Canada Frankfurt, Germany Munich, Germany Tokyo, Japan Osaka, Japan London, UK Guadalajara, Mexico Chennai, India Sydney, Australia Global Workforce of Over 4,000 Individuals Who Are Core to Our Mission and Our Platform, We Have a Presence in Over 71 Countries (1) Based on Management's Estimates for last two years ended December 31, 2021 DNL wcg Founded in 2012 30 Acquisition s since 2012 ~30% workforce hold advanced degrees ~93% Revenue With Our Technology#88 Our Large, Growing and Diversified Client Base Client Composition 5,000+ Pharma & CRO Clients 160,000+ Global Principal Investigators Ecosystem Engagement 290,000 Readers of WCG Publications 3,300+ Academic Medical Centers & Institutions 2.5mm Patients Engaged 80,000+ Annual Conference & Webinar Attendees Abbott Biogen Pfizer Shire Clinipace GIOVIA PPD PSI Large Biopharma 50 of 50 Top Pharma by Revenue abbvie BIOMARIN Eisal Otsuka Genentech Lilly Lilly MERCK REGENERON Allergan AMGEN AstraZeneca TEUN COVANCE MEOPACE Rho GILEAD CROS 8 of 8 Top CROS by Revenue -200 Small/Mid CROS ICON 6 NOVARTIS Roche Blue Chip Client Base PAREXEL premier Syneos esk SANOFI VERTEX integrim Pharm-Olam *ProTrials 00 Amicus CENTREXION SAREPTA Intercept IONIS PACIRA O EMORY HEALTHCARE PARTNERS Small & Mid-Cap Biopharma 4,000+ Akebia Tufts agios relypsa Spark Top 5 Clients Representing <25% of Total Revenue Conatusy Beifiene HEALTH SYSTEM Ucla Karyopharm ALECTOR #TESARO Institutions & Investigators 3,300+ Institutions & AMCS Epizyme Raplimune Revance TONIX NYU Langone RUTGERS U Medical Deter wcg DNL 2 Alnylam Celldex Incyte NEKTAR SAGE Trevena UFHealth#9Evidence of Our Impact - WCG's Significant Participation in FDA Approved Drugs FY 2020 New Therapeutic Agents Approved by FDA Breakthrough Therapies Oncology & Hematology Therapies Neurology & Psychiatry Therapies Total WCG Approved Involvement 53 46 18 17 6 16 17 6 % of Total 87% 89% 100% 100% >2WCG Business Lines 30 13 16 2 wcg % of Total in Q1 2021 87% DN L 100% 100% 100%#10WCG Connects the Entire Clinical Trial Ecosystem 10 We Have Relationships with and Have Served 3,300+ Institutions 160,000+ Global Principal Investigators (2) 10,000+ Sites We Have Relationships with and Have Served 5,000+ Biopharma and CRO Clients, of which 4,000+ are Small and Mid-cap Biopharma 50 of 50 Top Pharma), 8 of 8 Top CROS(¹) -200 Small/Mid CROS Sponsors / CROS + (1) By revenue. (2) Based on management estimates. (3) Per management's estimate for the last two years ended December 31, 2020. wcg knowledge base Sites - Institutions / Investigators Advocacy Groups An Expansive Presence: In 90% of All Global Clinical Trials(3) | 87% Participation in FDA Approvals Patient/ DN L wcg We Have Relationships with and Have Served 100+ Patient Advocacy Groups 2.5mm Patients in WCG-Supported Studies ⒸWCG 2021#11Our Proprietary Technology "Hardwires" Clients to the WCG Clinical Trial Ecosystem wcg knowledge base 31TB of Real-Time, Regulatory-Grade Data 11 investigatorSpace wcg SDE wcg SFA wcg IRBNet wcg eResearch Sponsors / CROS Sites - Institutions/ Investigators (1) According to management estimates for the two years ended December 31, 2020. + A go wcg QDSS wcg SafetyPortal wcg Safety Vigilance wcg TrialCTA wcg AIMS wcg DASH wcg aLearn wcg KMR Patient/ Advocacy Groups Daca Platform wcg IRB Connexus wcg Virgil wcg ConsentNow wcge my-patient com wcg Connect™ DNL wcg Client Connectivity 93%+ of WCG engagements delivered through our proprietary technology Real Time Data Each technology produces real-time data that continuously feeds our Knowledge Base 90% of All Global Trials(¹)#12Our Investment Thesis - New Approaches to Addressing Clinical Trial Pain Points Dimensions of the Pain Point 1 # The Pain Point Lengthy IRB Review Slow Trial Startup Delayed Patient Enrollment Burdensome Administrative Processes Use of Disparate Technologies 12 (1) Reflects industry data. (2) WCG Performance. Up to 6 Months for IRB Reviews and A Different IRB for Every Site Little Improvement in the Past Few Years 85% of Trials Are Behind on Patient Enrollment Requires 6 Months to Negotiate Contracts and Budgets Between Biopharma & Sites On Average, 6 Different Technology Solutions Are Used In A Single Clinical Trial WCG Value DNL wcg 95% Improvement in IRB Review Time 50% Reduction to 6 Months 33% improvement 42% participant diversity in large biopharma COVID-19 trial 37% Improvement in Contracts & Budgets Negotiation Time Single Integrated Platform Supporting All Clinical Trial Stakeholders, Enabling Data-Driven Insights#13WCG Served Market - Highly Specialized, Large, and Growing ($ in billions) $200 $180 $160 $140 $120 $100 $80 $60 $40 $20 13 | Total Global Pharma 1 1 R&D Spending $195 Total Source: Tufts CSDD, EvaluatePharma Total Clinical Trial Spend $89 Conducted by Pharma Companies $48.1 Outsourced to Pharma Services $40.5 Phases I-IV Ethical Review CTS - Study Planning & Site Optimization CTS - Patient Engagement CTS-Scientific & Regulatory Review Total WCG Markets Total Clinical Trial Spend, by Category $89 Phases I-IV by Service 2021 WCG TAM $0.7B 3.08 The Areas We Serve Are Growing Faster Than The Industry 2.08 $8.98 WCG Served Market DNL wcg 2021-23 TAM CAGR% 13% 19% 14% 7%#14Strong Track Record of Growth and Industry Transformation 14 Key Events 31% Revenue CAGR (2012-20) $53 ■ Revenue ($mm) Adjusted EBITDA ($mm)" $20 17% Organic Revenue CAGR (2012-20) 2012 2013 Transformed IRB Review 2014 35% Adj EBITDA CAGR (2012-20) 2015 Established New Standard for Predictive Site Selection 28% Organic Adj EBITDA CAGR (2012-20) (1) See appendix for a reconciliation of Adjusted EBITDA to the nearest GAAP measure. 2016 2017 Created New Paradigm for Patient Engagement $346 $146 2018 $413 $169 2019 Transforming Clinical Measurement Science $463 $218 2020 DNL wcg ~75% Visible Revenue (for the next twelve months) Predictable & Consistent Growth Unleashing Industry- Wide Clinical Trial Insights#15Majority of Growth Achieved Organically - As Evidenced by EBITDA Bridge Transformational Company Building EBITDA* ($ millions) 15 IRB CSO 2012 Adj EBITDA Margin 29% 2012 2012-14 2014-16 2016 2017 WIRBCopernicus IRBNetpharmsolutions fil ProPhase ThreaWire Aspireirb Midlands he New Clintrax Global karmadata CenterWatch ALLIANCE 2017 Organic EBITDA Growth (2012-20) 2017 FDANEWS ConsentNow VIGILARE MedAvante. KMR GROUP 2018 2019 2020 ACI AANALGESIC trifecta MCC pharmaseek Statistics-Collaborative DNL wcg 2020A wcg Adj EBITDA Margin >45%#16Profile of Segment Financial Performance 16 Ethical Review $239mm of Revenue 80% + Gross Margin Technology-Enabled IRB Regulatory Services Based on Fixed Fee FY 2020 Financial Results Clinical Trial Solutions $224mm of Revenue 45% + Gross Margin Technology-Enabled Specialty Solutions Based on Professional Clinical Services Fees DNL wcg#17WCG Expects to Grow Well in Excess of the Market 17 ◆ Our Ethical Review segment is mandated by the FDA and generates significant and reoccurring revenue, representing approximately 52% (1) of our total revenue ◆ CTS provides the largest growth opportunity for new product development, cross-sell opportunities and acquisitions ◆ WCG has long-standing, industry leading relationships and contracts with research sites, providing a further competitive moat 14% '21-23 TAM Expected CAGR Share Gains/ Cross-Sell New Product Development Components of WCG Expected Growth Acquisitions 20 - 25% Expected Long- Term Revenue CAGR Segment Ethical Review Clinical Trial Solutions (incl. M&A) Source: Tufts CSDD, EvaluatePharma Note: Long-term growth expectations are the Company's goals based on third-party TAM growth projections and should not be viewed as a guarantee of future performance or guidance for any period. Actual results may differ and such differences may be material. (1) Based on FY2020 revenue. TAM Expected CAGR 2021-2023 13% DNL 14% wcg WCG Long- Term Revenue CAGR 14-16% 25-30%#18Our Company 18 wcg™#19WCG is Organized to be a Powerful Engine of Change in Today's Dynamic Clinical Trials Industry Leading clinical and technical depth to navigate the most critical decision points in clinical trial progress 19 % wcg DNL wcg Ethical Review Segment Our WCG IRB and IBC Services maximize research participant protections and save essential time in pursuit of clinical discovery Clinical Trials Solutions Segment Our highly specialized services have been designed to address critical inflection points that can enhance or derail quality outcomes 52% of 2020 Revenue 48% of 2020 Revenue#20Ethical Review Segment (IRB): A Regulatory "Need to Have" in Every Clinical Trial IRBS - Required by Law ● Institutional Review Board (IRB) is an FDA- mandated component of all clinical trials . IRB formally FDA-designated to approve, monitor, and review biomedical and behavior research involving humans . IRBs are highly regulated by the FDA, the Department of Health and Human Services, and AAHRPP 20 Regular FDA Audits Conforming to Independent Accreditation (AAHRPP) ISO Certified Lean Six Sigma Certified Source: Tufts CSDD, EvaluatePharma (1) Based on revenue. 58,000+ Ethical Reviews Completed + wcg IRB About Us 10,000+ US-based Research Sites 8+8 3,300+ Academic Medical Top Pharma Centers & Institutions & CRO as Clients(¹) 160,000+ Global Research Sites 200+ Volunteer IRB Panel Members DNL wcg +13% *21-23 Est. TAM CAGR $239mm 2020 Revenue 80% Gross Margin#21. G The IRB Business Model - "Fee-based IRB Touchpoints" Provide Highly Reliable Revenue Stream IRB Responsibilities Factors Driving Our Growth Increased Trial Complexity Larger Clinical Trials Focus on Chronic and Degenerative Diseases Advancing Protocol Design Drug/Device/Diagnostic Combination Trials 21 Initial Protocol Review 0 Trial Close Out Annual Trial Review VEEN Changes in Investigators Investigator / Site Review wcg Revenue Generated from Each Touchpoint During the Clinical Trial Protocol Amendments Initial Patient Recruitment Review Initial Protocol Review Patient Communications MEEN Initial Investigator and Site Review DNL Initial Informed Consent Review wcg#22Visualizing Our CTS Contribution - Removing the Pain Points in Clinical Trials 22 Patient Recruitment & Enrollment Study Start-Up Regulatory Submissions WCG partners with sponsors, CROS, and sites to optimize clinical trials through highly specialized solutions Rapid site selection & initiation Accelerated enrollment through site-based support ONL wcg Highly qualified sites Improved submission readiness#23Clinical Trial Solutions Segment - Specialized Point Solutions Which Augment Our Clients' Trial Processes - Each Removing Critical Trial Pain Points 23 Ethical Review IRB IBC 8 Research Management +1 Data Study Planning & Site Optimization Benchmarking & Analytics Financial Management ↑ Site & Investigator Training Site Selection & Feasibility ↑ Data 8 88 Coverage Analysis Site CTMS Clinical Trial Solutions 直角 Patient Engagement Site Augmentation Study Insight Analytics Rater & Patient Training wcg knowledge base Data eConsent Clinical Assessments eCOA/ePRO Platform Scientific & Regulatory Review Trial Design & Protocol Planning Safety Letter Distribution Drug Safety / PV Statistical Consulting Data Independent Expert Committees wcg Medical Imaging#24Case Study: Centralized Global Vaccine Trial Huw 24 Large Biopharma Case Study: WCG Enrolled Over 32,000 of 44,000 Patients WCG's Support Resulted in 42% Patient Diversity . WCG played a crucial role in enrolling over 32,000 patients into Client's COVID-19 vaccine program . WCG supported Client in achieving 42% participant diversity in their COVID-19 trial "There is no way that we could have achieved our enrollment targets without WCG on our vaccine program... Because of WCG's success in our COVID vaccine program, we are asking ourselves why wouldn't we want that same performance for all vaccine trials going forward - COVID or otherwise?" Large Biopharma Global Clinical Trial Executive ONJEL wcg#25Case Study - Site Selection Large Global Biopharma Reduces Site Selection Timeline from Months to Days 25 WCG optimized site selection across a portfolio of over 40 studies, ranging from Phase I to Phase III. Previously, the site identification process took 8 to 10 weeks. ONL wcg 3 Days To identify high-performing sites for studies#26Case Study - Virtual Site Training Top 10 Biopharma Unburdening Sites to Move Faster with On Demand Virtual Training 26 On Demand Virtual Training Across a Sponsors Entire ↑ Portfolio of Trials WCG's on-demand training solution allowed the Sponsors investigators & study teams to complete training in real time, while eliminating redundant training. The WCG solution ensures the Sponsor maintains a perpetual state of inspection readiness through the ongoing qualification of Pls and Site staff in real time throughout the Trial. ONL wcg 98,166 Hours of redundant training eliminated over 4 years.#27Case Study - Site Performance Optimization Top Research Institution Grows Clinical Trials by 38% 27 WCG Led a Complete Research Office transformation for a program of over 100 trials across 40 hospitals, 4,000 integrated providers, 900 physician practices and outpatient facilities, and 3 million active patients. Results increase in industry trial study starts ONL 38% 37% 39% increase in patient enrollment decrease in study start-up timelines wcg "Partnering with WCG allowed us to build a patient- centered research program, while reducing costs and increasing revenue. This foundation gave us the platform to demonstrate how research positively impacts patient outcomes across our entire health system." -Executive Director#28Case Study - Drug Safety and Adverse Effect Management and Reporting Improving Compliance and Saving Our Clients Over $1B of Cost 28 00 WCG SafetyPortal is the industries most adopted safety document distribution platform, having innovated the space with the first "zero touch" fully automated "intelligent" system. Global CRO: 83 unique Sponsors across over a hundred studies supported by SafetyPortal since 2019 Large Biopharma: 100,000,000 safety letters distributed through the system on >2,000 studies across 110 countries. System saved nearly $80m in one year alone. ONL wcg Large Biopharma: Over 20,000 sites, 1,500 ethics committees, in support of >1,000 active studies using SafetyPortal for SUSAR distribution in 90+ countries.#29WCG is Alone in Offering an Integrated Suite of Technology-Enabled Solutions Addressing the Major Pain Points in Clinical Trials Ethical Review Ethical Review • Provides technology-enabled services that ensure clinical trials respect the rights and protect the welfare of patient participants Clinical Trial Solutions ( 29 Study Planning & Site Optimization • Provide sites and sponsors with integrated, turnkey services to identify, activate, and benchmark sites through deep scientific and clinical expertise and proprietary insights Patient Engagement • Precisely identify, recruit and retain the right patients, as well as rater training and eCOA solutions to enable trials that rely on subjective endpoints Scientific & Regulatory Review • Provide services that offer an integrated solution based on scientific expertise and safety services and technology. supporting strong compliance and reporting Select Providers of Niche Solutions A ADVARRA wcg Integrated Solutions Suite ORACLE + goBalto Niche/ Regional IRBS A ADVARRA ArisGlobal ELLIGO TrialSpark HEALTH JAVARA BIOCLINICA AN ERT COMPANY PRIMEVIGILANCE DNL wcg In-House IRBS at Institutions Small Offerings by Select CROS greenphire SIGNANT HEALTH ERT COGSTATE Science 37 Recruitment medidata yprime MEDABLE Acurian Companies PROPHARMA GROUP Niche Patient Cytel#3030 WCG is Not a CRO - We Make CROS More Cost Effective & Efficient What Makes WCG Different than a CRO? CROS are outsourcing generalists that run clinical trials from end-to-end on behalf of biopharma sponsors - WCG is a specialist that focuses only on 4 pain points of the trial process. CROS conduct clinical trial monitoring as a matter of regulatory obligation - WCG does not do clinical trial monitoring. CROS cannot be an IRB because they monitor clinical trials. This would be a conflict of interest. CROS are major clients of WCG -WCG supports CROS with our proprietary technology and specialty clinical solutions Outsourced Clinical Services (2020) Clinical Solution Clinical Monitoring Investigator Payments Laboratory Data Management Project Management Patient & Site Recruitment Technology Biostatistics Imaging Medical Writing Regulatory Quality Assurance Other IRB / Ethical Review Total CRO Revenue ($B) $ 7.4 $ 5.1 $ 4.2 $ 4.0 $ 3.4 $ 3.4 $ 3.1 $ 2.5 $ 1.5 $ 1.2 $ 1.1 $ 0.9 $ 0.7 N/A $ 38.4 CRO Conflicted WCG Revenue ($B) N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A WCG Clinical $ 0.224 Trial Solutions Segment $ 0.239 DN L $0.463 wcg Source: Statista (June 2021), Industry Standard Research (May 2019), and management estimates. Note: Outsourced Clinical Services includes CSO, CRO, and other outsourced services. WCG Ethical Review Segment#3131 WCG Clinical Services Support and Enhance CROS - Not Competitive With Our Ethical Review Solutions Support All CROS Our Benchmarking & Analytics Solutions Support All CROS Our Technologies Support All CROS Our Proprietary Technologies dh Our High-touch Science & Specialty Solutions wcg Empowering CROS CRO'S Rely On & Benefit From... Our "Gold-Standard" Reputation for Excellence EFEC Our Longstanding, Contractual Relationships with Sites CROS Rely on Our Scientific Expertise CROS Rely on Our Relationships with Sites WCG Strengthens CROS' Competitive Positioning Our Regulatory Relationships Our Data wcg#32WCG and CROS - Complementary Business Models - We Support The Entire CRO Industry: Including 8 of the Top 8 CRO Business Model Client Engagement: Trial-by-Trial Bookings & Execution Business Model: Staffing-Centric Highly Competitive Environment Among CROS Dependent on Third Parties for Specialized Technology & Science Ad hoc Site & Patient Relationships: Trial-by-Trial High Employee Turnover Mature Business Models Growing in line with R&D Spending EBITDA Margins: -15-25% Revenue Growth: -8-10% 32 wcg WCG Business Model Client Engagement: Sustained Platform Connecting All Clinical Trial Stakeholders Business Model: Technology-centric with Data-driven Insights Unique Integrated Solutions Without Direct Competition Adj. EBITDA Margins: -45% A Leading Provider of Specialized Technology & Science to CROS Institutionalized Contractual Relationships with Sites & Patient Advocacy Groups Commitment to Mission & Social Responsibility Leads to High Employee Retention Differentiated Growth Profile Driven by Purpose-Built Solutions Expected Long Term Revenue CAGR: 20-25% DN L wcg™ (1) Long-term growth expectations are the Company's goals based on third-party TAM growth projections and should not be viewed as a guarantee of future performance or guidance for any period. Actual results may differ, and such differences may be material..#33Increasing Client Expansion Through Cross-Selling (2016 to 2021) 2016 Q1 Customer # 1 CRO 2 Large Blopharm.a 3 CRO 4 Large Biopharma 5 Large Blopharma 6 Large Biopharma CRO 7 8 Large Biopharma 9 Large Biopharma 10 Large Biopharma 11 Large Biopharma 12 Large Biopharma 13 CRO 14 Large Biopharma 15 Large Blopharma 16 Large Biopharma 17 CRO 18 Large Biopharma 19 CRO 20 CRO 21 Large Biopharma 22 CRO 23 Large Biopharma 24 CRO 25 Large Blopharma 26 CRO 27 Institution 28 Large Biopharma 29 Large Biopharma 30 Institution 33 IRB Feasibility. Selection & Contracts & Budgets Benchmarking & Analytics eCOA/ePRO Assessment Adjudication & Drug Safety Services SafetyPortal Market Insights MSA? Duration of Relationship (Years) 15 18 10 12 13 8 17 22 8 9 12 20 10 11 20 18 21 8 14 22 9 12 11 9 2021 Q1 w NL wcg Top 30 Accounts MSAs with 29 of Top 30 Accounts Bookings growing at a 30% compound annual growth rate from 2018 to Q1 2021 Resilient through pandemic - Bookings in 2020 grew at 20% $1.6bn opportunity from expanding existing solutions within top 25 clients#34%% wcg Thank You & Q&A.#35WCG Strategic Growth Initiatives Are Expected to Sustain Topline Growth Capitalize on Our Large and High-Growth Markets +14% 2021-2023 TAM growth CAGR 35 Source: Tufts CSDD, EvaluatePharma 2 Grow Within Our Existing Client Base: Share Gains & Cross Sell $1.6bn opportunity from expanding existing solutions within top 25 clients Further Leverage the WCG Clinical Trial Ecosystem™, the WCG Knowledge Base™ and Our Proprietary Technology Platform 31TB of Real-Time, Regulatory- Grade Data ONL 30 acquisitions since inception in 2012 wcg Continuously Expand Our Platform Through the Acquisition of New Capabilities#36Appendix 36 wcg#37GAAP Net Income / (Loss) to Adjusted EBITDA Reconciliation ($ in millions) Net (Loss) Income Interest Expense Income Tax Benefit Depreciation and Amortization Stock Option Expense Integration Cost(¹) Acquisition Related Adjustments (2) Restructuring Costs(3) Litigation Costs(4) Change in Value of Contingent Consideration (5) Management Fees(6) Charitable Contribution() Other(8) Adjusted EBITDA 37 Successor 2020 $(95.3) 91.3 (38.9) 205.7 4.6 20.2 21.2 5.2 2.8 1.4 0.1 0.1 218.4 Year Ended December 31, Predecessor 2019 $18.2 55.4 (0.3) 64.6 12.2 14.9 (0.0) 1.0 2.1 0.5 (6) Includes management fee paid to our prior sponsor in 2019 and 2020. Upon completion of the Transaction on January 8, 2020, this management fee was eliminated. (7) Includes a contribution to the WCG Foundation, a charitable organization for developing grants and programs for education. (8) Reflects one-time costs related to the preparation for this offering. DN L wcg 168.7 (1) Includes certain integration costs in connection with mergers and acquisitions, including the Transaction, the Trifecta acquisition, and other acquisitions made by WCG. These costs include system integration costs, marketing and rebranding costs, and certain payroll and employee related expenses. (2) Includes legal and professional costs related to the Company's mergers and acquisitions. Costs related to the Transaction for the years ended December 31, 2020 and 2019 were $15.0 million and $10.2 million, respectively. Costs related to the Trifecta acquisition were $0.9 million, which occurred during the year ended December 31, 2020. Costs related to other acquisitions made by WCG were $5.3 million for the year ended December 31, 2020 and $4.7 million for the year ended December 31, 2019. (3) Includes costs related to restructuring initiatives and the closing of a product line, and impairment of related assets. (4) Includes litigation costs outside of the ordinary course of business related to settlement with certain employees. (5) Includes valuation adjustments for acquisition-related contingent consideration, which is subject to remeasurement at each balance sheet date. Any change in the fair value of such acquisition-related contingent consideration is reflected in our consolidated statements of operations as a change in fair value of the liability. We adjust the carrying value of the acquisition-related contingent consideration until the contingency is finally determined or final payment is made.#38To Better Understand WCG - Clinical Trial Basics Clinical Trials Phase I - IV 38 DNL wcg • A Clinical Study is an experiment designed to answer specific questions about possible new treatments or new ways of using known treatments. The procedures governing a trial are described in a Protocol. Clinical trials are done to determine whether new drugs, devices, diagnostics or treatments are safe and effective using consenting human participants Strictly Regulated By Global Drug Approval Agencies: In the US, it is the FDA A Regulatory Approval is required before any Drug, Device, or Diagnostic can be made commercially available Clinical trials advance through four phases to test a treatment, find the appropriate dosage, and look for side effects. If, after the first three phases, researchers find a drug or other intervention to be safe and effective, the FDA approves it for clinical use and continues to monitor its effects • Phase I trial tests an experimental treatment on a small group of often healthy people (20 to 80) to judge its safety and side effects and to find the correct drug dosage. • Phase II trial uses more people (100 to 300). While the emphasis in Phase I is on safety, the emphasis in Phase II is on effectiveness. This phase aims to obtain preliminary data on whether the drug works in people who have a certain disease or condition. This phase can last several years. • Phase III trial gathers more information about safety and effectiveness, studying different populations and different dosages, using the drug in combination with other drugs. The number of subjects usually ranges from several hundred to about 50,000 people. If the FDA agrees that the trial results are positive, it will approve the experimental drug or device. • Phase IV trial for drugs or devices takes place after the FDA approves their use. A device or drug's effectiveness and safety are monitored in large, diverse populations. Sometimes, the side effects of a drug may not become clear until more people have taken it over a longer time period#39WCG's Evolution - Transforming an Industry WCG 2.0 Leveraging IRB to Serve Broader Clinical Trial Ecosystem WCG 1.0 Pioneers of an Industry wcg 2012 WCG Founded 1968 Western IRB (WIRB) is founded, pioneering the concept of Independent Ethical Review WIRB WCG launches Clinical Trial Solutions Organization 2014 Transforming Ethical Review 2013 WCG transforms IRB review process by introducing Single Review Solution WCG recapitalizes to fund continued industry transformation 2016 2015 SaaS platform to provide data- driven insights for clients to analyze optimal sites and manage resources, timelines, and budgets > wcg Single Review Solution * wcg Predict Organized into five fully integrated operating business lines 2018 39 (1) Based on management's estimate for the last 2 years ended Dec 31, 2020. (2) Based on FDA data and management's calculation. Accelerating Clinical Trials 2017 WCG creates new paradigm to improve patient engagement wcg ThrealNiCE wcg MedAvante-ProPhase WCG 3.0 Integrated Solutions - Powerful Value Wcg ACI CLINICAL approvals 2019-2020 2018 MAGI, the leading clinical trial conference, expands WCG thought leadership platform Supported 87% of FDA new drug wcg VIGILARE Creates industry's largest network of scientific & regulatory experts 2018 wcg MAGI 2020 2020+ ONL Delivering Actionable Insights WCG 4.0 2019 WCG's presence in 90% of global clinical trials feeds the WCG Knowledge Base™ to harness and deliver actionable trial insights" wcg wcg knowledge base